The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs.

This study is currently recruiting participants.

Study NCT00354627 Information provided by Tibotec Pharmaceuticals, Ireland

First Received: July 18, 2006 Last Updated: October 29, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	December 2013
Estimated Primary Completion Date:	April 2011 (Final data collection date for primary outcome measure)